Skip to content

Topic

AI Drug Discovery

The use of machine learning and generative AI to identify, design, and prioritize drug candidates, predicting molecular structures and biological targets.

Current stories

build1 publisher

Microsoft's Quine closes the loop between a biology model and the wet lab

Microsoft says its Quine system narrowed thousands of compounds to a pancreatic cancer shortlist in one weekend. For research-AI teams, the part to study is the harness that sends lab results back into the next question, and nobody has yet measured its value across cycles.

Publishers:theneuron.ai

Reality

Evidence35
Adoption
Insufficient
Hype gap+30
Incentives65
Confidence40
product3 publishers

Six independently built ageing clocks agree on the same 42 patients from Insilico's lung trial

The six clocks agreeing matters more than the years they report, because a drug that quiets an inflamed lung moves the same blood proteins whether or not it slows ageing anywhere else.

Perspective Coverage

3 publishers
Builder
Builder 45%
Operator
Operator 32%
Investor
Investor 23%

Reality

Evidence42
Adoption5
Hype gap+45
Incentives70
Confidence62
invest3 publishers

Basecamp Research raises more in one round than in its first seven years combined

S32 led a $140M round that takes Basecamp Research's total funding to $225M since 2019. Two of the sixteen named backers, NVIDIA and Anthropic's Anthology Fund, are also partners on the dataset its models train on.

Perspective Coverage

3 publishers
Builder
Builder 30%
Operator
Operator 15%
Investor
Investor 55%

Reality

Evidence55
Adoption
Insufficient
Hype gap+40
Incentives75
Confidence60
product5 publishers

Anthropic puts its biology claims on the bench in a new Bay Area wet lab

The company's head of life sciences told Reuters that real lab work is still the final test in biology. Anthropic has not said which experiments the lab is running, and it has yet to run a clinical trial.

Perspective Coverage

5 publishers
Builder
Builder 28%
Operator
Operator 35%
Investor
Investor 37%

Reality

Evidence55
Adoption40
Hype gap+30
Incentives70
Confidence57

Earlier coverage

  1. Insilico credits its AI with a drug discovery. The patent credits five humans.

    Product · August 21, 2026 · 1 publisher

  2. An 'exercise pill' clears Phase I: 88 healthy adults, no GI trouble, no efficacy yet

    Product · August 19, 2026 · 1 publisher

  3. Anthropic's protein binders got tested by outside labs. The benchmark is still Anthropic's.

    Product · August 19, 2026 · 1 publisher

  4. Vivodyne is spending venture money on wet-lab throughput, not bigger models

    Build · August 19, 2026 · 2 publishers

  5. Vivodyne says the AI drug bottleneck is human tissue data, not model capability

    Product · August 19, 2026 · 1 publisher

  6. The judge is the product: building the scorer for an AI malaria drug leaderboard

    Build · August 14, 2026 · 1 publisher